Policy & Regulation
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C's Potential as an Effective Treatment for Hair Loss
23 November 2022 - - Preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, has been published in Molecular Pharmaceutics, South Korea-based RNAi therapeutics developer OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) said.

The company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology.

OLX104C reduces the expression of androgen receptor, one of the key factors that cause androgenetic alopecia, which results in the suppression of the hair cycle transition from anagen to telogen phase.

The paper "Efficacy of Asymmetric siRNA Targeting Androgen Receptor for the Treatment of Androgenetic Alopecia" is based on the preclinical study on OLX104C, jointly conducted by OliX and the research team of Ik Jun Moon, M.D., Ph.D. & Chong-hyun Won, M.D., Ph.D. of University of Ulsan College of Medicine, Asan Medical Center.

The research team demonstrated the efficacy of AR reduction, hair loss inhibition, and long duration of action in primary cultured human follicle dermal papilla cells (HFDPC) and rodent models of hair loss.

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.